ND Biosciences

Next-Generation Therapeutics for Neurodegenerative diseases

Play Video
About us

About ND Biosciences

ND Biosciences is a spinoff from the Swiss Federal Institute of Technology in Lausanne (EPFL), that was founded to develop next-generation therapeutics for neurodegenerative diseases (NDs), such as Parkinson’s and Alzheimer’s Disease.

ND Biosciences’s therapeutic development programs are enabled by an integrated suite of novel, validated and patented drug-discovery platforms that have been developed over the past 15 years at the EPFL, and that allow for the first time to address the limitations of previously-applied technologies, and that accurately reproduce:

1) The diversity, as well as the structural and biochemical properties of pathogenic protein aggregates as observed in patient brains, thereby enabling more accurate antigen generation for drug development

2) The different stages of protein aggregation in a suite of cellular models of disease, including the only available models reproducing early and terminal aggregation stages leading to neurodegeneration, thereby enabling assessment of efficacy and identification of next-generation hits using translationally-relevant models

our science

our Publications

The technologies, innovative tools and discovery platforms deployed by ND Biosciences are based on more than 15 years of research that was carried out at the EPFL, and are well-documented in many high impact peer-reviewed publications.

Latest News

Supported by